Rationale for CXCR2 Antagonists in Treating COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Journal of Experimental Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Blocking Inflammation on the Way: Rationale for CXCR2 Antagonists for the Treatment of COVID-19
J Exp Med 2020 Sep 07;217(9)e20201342, LM Koenig, DFR Boehmer, P Metzger, M Schnurr, S Endres, S RothenfusserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.